AU2012327247B2 - Transdermal delivery system - Google Patents

Transdermal delivery system Download PDF

Info

Publication number
AU2012327247B2
AU2012327247B2 AU2012327247A AU2012327247A AU2012327247B2 AU 2012327247 B2 AU2012327247 B2 AU 2012327247B2 AU 2012327247 A AU2012327247 A AU 2012327247A AU 2012327247 A AU2012327247 A AU 2012327247A AU 2012327247 B2 AU2012327247 B2 AU 2012327247B2
Authority
AU
Australia
Prior art keywords
buprenorphine
transdermal therapeutic
therapeutic system
adhesive layer
sensitive adhesive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012327247A
Other languages
English (en)
Other versions
AU2012327247A1 (en
Inventor
Thomas Hille
Helen Elizabeth Johnson
Gillian Elizabeth Mundin
Kevin John Smith
Gabriel WAUER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47754872&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012327247(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Publication of AU2012327247A1 publication Critical patent/AU2012327247A1/en
Application granted granted Critical
Publication of AU2012327247B2 publication Critical patent/AU2012327247B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2012327247A 2011-12-12 2012-12-12 Transdermal delivery system Ceased AU2012327247B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161569609P 2011-12-12 2011-12-12
US61/569,609 2011-12-12
PCT/IB2012/002973 WO2013088254A1 (en) 2011-12-12 2012-12-12 Transdermal delivery system comprising buprenorphine

Publications (2)

Publication Number Publication Date
AU2012327247A1 AU2012327247A1 (en) 2013-06-27
AU2012327247B2 true AU2012327247B2 (en) 2015-12-24

Family

ID=47754872

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012327247A Ceased AU2012327247B2 (en) 2011-12-12 2012-12-12 Transdermal delivery system

Country Status (26)

Country Link
US (4) US20140363487A1 (enExample)
EP (1) EP2790685B1 (enExample)
JP (2) JP6289378B2 (enExample)
KR (1) KR102014565B1 (enExample)
CN (2) CN107669662A (enExample)
AP (1) AP4036A (enExample)
AR (1) AR089201A1 (enExample)
AU (1) AU2012327247B2 (enExample)
BR (1) BR112014014137A2 (enExample)
CA (1) CA2858531C (enExample)
CL (1) CL2014001559A1 (enExample)
CO (1) CO7000779A2 (enExample)
CR (1) CR20140321A (enExample)
DE (1) DE112012005185T5 (enExample)
EA (1) EA201491164A1 (enExample)
ES (1) ES2647516T3 (enExample)
GB (1) GB2512007B8 (enExample)
IL (1) IL233025A0 (enExample)
MX (1) MX352795B (enExample)
PE (1) PE20142341A1 (enExample)
PH (1) PH12014501231A1 (enExample)
PL (1) PL2790685T3 (enExample)
SG (2) SG10201604754VA (enExample)
TN (1) TN2014000233A1 (enExample)
TW (1) TW201338813A (enExample)
WO (1) WO2013088254A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
WO2013006643A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA3202964A1 (en) 2011-12-06 2013-06-13 Delta Faucet Company Ozone distribution in a faucet
EP2790685B1 (en) * 2011-12-12 2017-08-16 LTS LOHMANN Therapie-Systeme AG Transdermal delivery system comprising buprenorphine
US9566241B2 (en) * 2012-02-21 2017-02-14 Auburn University Buprenorphine nanoparticle composition and methods thereof
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
LT2810646T (lt) 2013-06-04 2016-10-25 Lts Lohmann Therapie-Systeme Ag Transderminė tiekimo sistema
CN105358139B (zh) 2013-07-03 2020-10-16 Lts罗曼治疗方法有限公司 具有电子元件的经皮治疗系统
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
ES2954087T3 (es) * 2014-05-20 2023-11-20 Lts Lohmann Therapie Systeme Ag Sistema de administración transdérmica que incluye un mediador de interfase
CA2948220C (en) 2014-05-20 2023-06-20 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
CN106456567A (zh) 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 薬剤送達方法及びシステム
SG11201707350TA (en) * 2015-03-10 2017-10-30 Rhodes Tech Acetate salt of buprenorphine and methods for preparing buprenorphine
US10679516B2 (en) 2015-03-12 2020-06-09 Morningside Venture Investments Limited Craving input and support system
EP3067050A1 (en) 2015-03-13 2016-09-14 Acino AG Transdermal therapeutic system with an overtape comprising two adhesive layers
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
EP3349737A4 (en) * 2015-09-14 2019-05-15 Amneal Pharmaceuticals LLC SYSTEM FOR TRANSDERING
CN115093008B (zh) 2015-12-21 2024-05-14 德尔塔阀门公司 包括消毒装置的流体输送系统
RU2018133932A (ru) 2016-04-01 2020-05-12 Терапьютиксмд, Инк. Фармацевтическая композиция стероидного гормона
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US11285306B2 (en) 2017-01-06 2022-03-29 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
WO2019064026A1 (en) 2017-09-29 2019-04-04 Orexo Ab NEW PHARMACEUTICAL COMPOSITIONS
GB201716830D0 (en) 2017-10-13 2017-11-29 Cambrex Charles City Inc New Process
BR112020018607A2 (pt) 2018-03-13 2020-12-29 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico compreendendo um polímero híbrido de silicone acrílico
WO2019175106A1 (en) 2018-03-13 2019-09-19 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system comprising a silicone acrylic hybrid polymer
BR112020018300A2 (pt) 2018-03-13 2020-12-22 Lts Lohmann Therapie-Systeme Ag Sistema terapêutico transdérmico compreendendo um polímero híbrido de silicone e acrílico
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
WO2020102695A1 (en) 2018-11-16 2020-05-22 Cti (Assignment For Benefit Of Creditors) Llc Thermally regulated transdermal drug delivery system
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
CN113952319A (zh) * 2021-11-30 2022-01-21 烟台大学 一种含丁丙诺啡的骨架型透皮贴剂及其制备方法
CN114397411A (zh) * 2021-12-14 2022-04-26 苏州高迈药业有限公司 一种评价利丙双卡因乳膏的方法
WO2024040897A1 (zh) * 2022-08-24 2024-02-29 新领医药技术(深圳)有限公司 沙利度胺或其类似物透皮贴剂及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996019975A1 (de) * 1994-12-24 1996-07-04 Lts Lohmann Therapie-Systeme Gmbh Transdermale resorption von wirkstoffen aus unterkühlten schmelzen
WO2004014336A2 (de) * 2002-08-09 2004-02-19 Grünenthal GmbH Opiod-rezeptor-antagonisten in transdermalen systemen mit buprenorphin
US20100119585A1 (en) * 2006-11-21 2010-05-13 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for administering the active substance buprenorphine

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US119585A (en) * 1871-10-03 Improvement in horse-collars and hames
GB1136214A (en) 1965-06-15 1968-12-11 Reckitt & Sons Ltd Thebaine and oripavine derivatives
US3474101A (en) 1960-09-05 1969-10-21 Reckitt & Sons Ltd Thebaine and oripavine derivatives
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
CA2002299A1 (en) 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
DE3939376C1 (enExample) * 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5240711A (en) 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5635203A (en) * 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19922662C1 (de) 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
BR0012152A (pt) 1999-07-02 2002-03-12 Lohmann Therapie Syst Lts Sistema de microrreservatórios na base de polissiloxanos e solventes ambifìlicos
DE19958554C2 (de) 1999-07-02 2002-06-13 Lohmann Therapie Syst Lts Mikroreservoirsystem auf Basis von Polysiloxanen und ambiphilen Lösemitteln und ihre Herstellung
WO2001014336A1 (en) * 1999-08-20 2001-03-01 Nippon Kayaku Kabushiki Kaisha Benzene derivatives substituted by aromatic ring and process for producing the same
ATE431145T1 (de) 2000-02-08 2009-05-15 Euro Celtique Sa Missbrauchssichere orale opioid-agonist zubereitungen
JP4659943B2 (ja) * 2000-02-25 2011-03-30 帝三製薬株式会社 塩酸ブプレノルフィン含有貼付剤
US6844727B2 (en) * 2000-06-28 2005-01-18 Baker Hughes Incorporated Method and apparatus of reducing ringing in a nuclear magnetic resonance probe
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
WO2002083135A2 (en) 2001-02-16 2002-10-24 Grünenthal GmbH Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence
DE10141651B4 (de) 2001-08-24 2007-02-15 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung
DE10213772A1 (de) 2002-03-27 2003-10-09 Gruenenthal Gmbh Zusammenhängende Einheit aus vereinzelbaren transdermalen therapeutischen Systemen
US20050118245A1 (en) 2002-03-27 2005-06-02 Wilsmann Klaus M. Assembled unit consisting of individually separable, transdermal, therapeutic systems
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
US7270830B2 (en) 2002-12-13 2007-09-18 Purdue Pharma L.P. Transdermal buprenorphine dosage regimen for analgesia
RU2324372C2 (ru) 2003-03-25 2008-05-20 Моринда, Инк. Селективное ингибирование продукции эстрогена и обеспечение эстрогенного действия в организме человека
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US7182955B2 (en) * 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
DE102004045599A1 (de) 2004-09-17 2006-03-23 Grünenthal GmbH System zur sequentiellen, transdermalen Verabreichung von systemisch wirksamen Substanzen
DE102004062647A1 (de) 2004-12-21 2006-06-29 Kronotec Ag Holzfaserdämmstoffplatte bzw.- matte
DE102004062614B4 (de) 2004-12-24 2011-12-29 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit aktivierbarer Übersättigung und kontrollierter Permeationförderung sowie Verfahren zu dessen Herstellung
DE102006054732B4 (de) 2006-11-21 2010-12-30 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit Ionenpaar-Mikroreservoiren
EP2366388A1 (de) 2010-03-17 2011-09-21 Ratiopharm GmbH Nicht-okklusives transdermales therapeutisches System zur Verabreichung von Buprenorphin
EP2790685B1 (en) * 2011-12-12 2017-08-16 LTS LOHMANN Therapie-Systeme AG Transdermal delivery system comprising buprenorphine
AU2013205080B2 (en) 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
LT2810646T (lt) 2013-06-04 2016-10-25 Lts Lohmann Therapie-Systeme Ag Transderminė tiekimo sistema

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996019975A1 (de) * 1994-12-24 1996-07-04 Lts Lohmann Therapie-Systeme Gmbh Transdermale resorption von wirkstoffen aus unterkühlten schmelzen
WO2004014336A2 (de) * 2002-08-09 2004-02-19 Grünenthal GmbH Opiod-rezeptor-antagonisten in transdermalen systemen mit buprenorphin
US20100119585A1 (en) * 2006-11-21 2010-05-13 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system for administering the active substance buprenorphine

Also Published As

Publication number Publication date
US20170049713A1 (en) 2017-02-23
NZ626535A (en) 2017-02-24
CN107669662A (zh) 2018-02-09
CO7000779A2 (es) 2014-07-21
WO2013088254A1 (en) 2013-06-20
EP2790685A1 (en) 2014-10-22
HK1201760A1 (en) 2015-09-11
HK1203048A1 (en) 2015-10-16
AR089201A1 (es) 2014-08-06
CA2858531A1 (en) 2013-06-20
BR112014014137A2 (pt) 2017-06-13
IL233025A0 (en) 2014-07-31
US20140363487A1 (en) 2014-12-11
KR20140101858A (ko) 2014-08-20
GB2512007A8 (en) 2017-06-28
GB2512007B (en) 2017-04-26
US20160120823A1 (en) 2016-05-05
AU2012327247A1 (en) 2013-06-27
MX2014007020A (es) 2014-07-14
GB2512007B8 (en) 2017-06-28
GB2512007A (en) 2014-09-17
PL2790685T3 (pl) 2018-04-30
US20200306204A1 (en) 2020-10-01
MX352795B (es) 2017-12-07
AP4036A (en) 2017-02-22
AP2014007779A0 (en) 2014-07-31
KR102014565B1 (ko) 2019-08-26
JP2017036304A (ja) 2017-02-16
DE112012005185T5 (de) 2014-08-28
ES2647516T3 (es) 2017-12-22
PH12014501231A1 (en) 2014-09-08
GB201412385D0 (en) 2014-08-27
CR20140321A (es) 2014-11-13
TN2014000233A1 (en) 2015-09-30
CL2014001559A1 (es) 2014-10-03
TW201338813A (zh) 2013-10-01
SG10201604754VA (en) 2016-08-30
EA201491164A1 (ru) 2014-10-30
JP6289378B2 (ja) 2018-03-07
EP2790685B1 (en) 2017-08-16
US9549903B2 (en) 2017-01-24
JP2015500329A (ja) 2015-01-05
SG11201403162XA (en) 2014-10-30
CN104114161A (zh) 2014-10-22
PE20142341A1 (es) 2015-01-17
CA2858531C (en) 2019-12-17

Similar Documents

Publication Publication Date Title
AU2012327247B2 (en) Transdermal delivery system
US20200253957A1 (en) Transdermal delivery system
US12138353B2 (en) Transdermal therapeutic system containing asenapine
HK1203048B (en) Transdermal delivery system comprising buprenorphine
NZ626535B2 (en) Transdermal delivery system comprising buprenorphine

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ HILLE, THOMAS; WAUER, GABRIEL; SMITH, KEVIN JOHN; MUNDIN, GILLIAN ELIZABETH AND JOHNSON, HELEN ELIZABETH

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired